My take on the Covid back-burner is that it has not been abandoned, merely set aside while looking at indications that offer substantial clinical trial numbers. Also considering potential competition and then there's funding.

IMO, if a suitable partner approached CA with a trial for long haulers, he would grab it in a heartbeat.

But then again, I was wrong as recently as last week.